These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 909077)

  • 21. Changes of blood pressure, plasma renin activity and plasma aldosterone concentration following the infusion of Sar1-Ile8-angiotensin II in hypertensive, fluid and electrolyte disorders.
    Yamamoto T; Doi K; Ogihara T; Ichihara K; Hata T; Kumahara Y
    Prog Biochem Pharmacol; 1976; 12():174-89. PubMed ID: 1019163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H-77: a potent new renin inhibitor. In vitro and in vivo studies.
    Szelke M; Leckie BJ; Tree M; Brown A; Grant J; Hallett A; Hughes M; Jones DM; Lever AF
    Hypertension; 1982; 4(3 Pt 2):59-69. PubMed ID: 7040240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of dog renin activity by pepstatin A.
    Miyazaki M; Komori T; Okunishi H; Toda N
    Jpn Circ J; 1979 Sep; 43(9):818-23. PubMed ID: 501901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Renin inhibitory factor in renal hypertension--an attempt in determining renin inhibitory capacity of the plasma].
    Funyu T; Nigawara K; Ono K; Yagihashi Y; Kawamata A
    Nihon Jinzo Gakkai Shi; 1977 Mar; 19(3):177-87. PubMed ID: 560579
    [No Abstract]   [Full Text] [Related]  

  • 26. Soluble pepstatins: a new approach to blockade in vivo of the renin-angiotensin system.
    Evin G; Gardes J; Kreft C; Castro B; Corvol P; Menard J
    Clin Sci Mol Med Suppl; 1978 Dec; 4():167s-169s. PubMed ID: 282046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New inhibitors of human renin tested in vitro and in vivo in the anaesthetized baboon.
    Tree M; Atrash B; Donovan B; Gamble J; Hallett A; Hughes M; Jones DM; Leckie B; Lever AF; Morton JJ
    J Hypertens; 1983 Dec; 1(4):399-403. PubMed ID: 6398331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation of human renin inhibitor from soybean: soyasaponin I is the novel human renin inhibitor in soybean.
    Takahashi S; Hori K; Shinbo M; Hiwatashi K; Gotoh T; Yamada S
    Biosci Biotechnol Biochem; 2008 Dec; 72(12):3232-6. PubMed ID: 19060406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Competitive inhibitors of renin. A review.
    Poulsen K; Burton J; Haber E
    Prog Biochem Pharmacol; 1976; 12():135-41. PubMed ID: 14338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of propranolol on blood pressure and renin in renal hypertension in the rat.
    Fernandes M; Onesti G; Fiorentini R; Gould AB; Kim KE; Swartz C
    Clin Sci Mol Med; 1977 Jan; 52(1):107-9. PubMed ID: 606459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.
    Luly JR; BaMaung N; Soderquist J; Fung AK; Stein H; Kleinert HD; Marcotte PA; Egan DA; Bopp B; Merits I
    J Med Chem; 1988 Dec; 31(12):2264-76. PubMed ID: 3143009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma renin activity in hypertensive rats after treatment with renin preinhibitor.
    Sen S; Smeby RR; Bumpus FM
    Am J Physiol; 1969 Mar; 216(3):499-503. PubMed ID: 4303901
    [No Abstract]   [Full Text] [Related]  

  • 33. Synthesis and renin inhibitory properties of a new soluble pepstatin derivative.
    Gardes J; Evin G; Castro B; Corvol P; Menard J
    J Cardiovasc Pharmacol; 1980; 2(5):687-98. PubMed ID: 6157960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.
    Raddatz P; Minck KO; Rippmann F; Schmitges CJ
    J Med Chem; 1994 Feb; 37(4):486-97. PubMed ID: 8120867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of lysophosphatidylethanolamine analogs that inhibit renin activity.
    Turcotte JG; Yu CS; Lee HL; Pavanaram SK; Sen S; Smeby RR
    J Med Chem; 1975 Dec; 18(12):1184-90. PubMed ID: 1195274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of human plasma renin activity by pepstatin.
    Guyene TT; Devaux C; Menard J; Corvol P
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1301-6. PubMed ID: 12191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo inhibition of renin by fatty acids.
    Kotchen TA; Welch WJ; Talwalkar RT
    Am J Physiol; 1978 Jun; 234(6):E593-9. PubMed ID: 665762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic phosphatidylethanolamines as renin inhibitors.
    Miyazaki M; Yamamoto K
    Proc Soc Exp Biol Med; 1977 Sep; 155(4):468-73. PubMed ID: 896796
    [No Abstract]   [Full Text] [Related]  

  • 39. Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.
    Repine JT; Himmelsbach RJ; Hodges JC; Kaltenbronn JS; Sircar I; Skeean RW; Brennan ST; Hurley TR; Lunney E; Humblet CC
    J Med Chem; 1991 Jul; 34(7):1935-43. PubMed ID: 2066966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel nonpeptidic, orally active renin inhibitor.
    Morishima H; Koike Y; Nakano M; Atsuumi S; Tanaka S; Funabashi H; Hashimoto J; Sawasaki Y; Mino N; Nakano M
    Biochem Biophys Res Commun; 1989 Mar; 159(3):999-1005. PubMed ID: 2495004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.